HealthLynked Names George O'Leary Interim CFO, Eliminates COO Role Amid Nasdaq Uplisting Push
HLYK has more than doubled off its 52-week low of $1.06 on elevated volume (3.3× avg).
Summary
HealthLynked appointed George O'Leary as part-time Interim CFO and eliminated the COO position, restructuring leadership to support a Nasdaq uplisting and a planned $7.5 million capital raise.
Key Events · Executive and Board Changes · HLYK
-
Interim CFO Appointed
Effective July 13, 2026, George O'Leary—a director and former CFO—was appointed part-time Interim CFO, earning $15,000 per month plus 35,000 options that vest only upon Nasdaq listing approval.
-
CFO Transitioned Out
Jeremy Daniel ceased serving as CFO and moved to a corporate accounting role; no disagreement was cited.
-
COO Position Eliminated
The COO role is being eliminated, and Duncan McGillivray will depart on July 24, 2026, transitioning to Senior Strategic Advisor on an as-needed basis.
-
Nasdaq Uplisting and Financing Goal
O'Leary's primary mandate is to secure a Nasdaq Capital Market listing and assist in a planned $7.5 million institutional equity financing post-approval.
Analysis · HLYK · Industrial Applications And Services
In a race toward a Nasdaq uplisting, HealthLynked is overhauling its executive team. The company brought back former CFO George O'Leary on a part-time basis, paying him $15,000 monthly plus 35,000 options that vest only if Nasdaq approves the listing. Simultaneously, it pushed out the sitting CFO and eliminated the COO role entirely. The moves signal a last-ditch effort to cut costs and install a finance chief with capital markets experience to execute the $7.5 million institutional financing planned after a potential Nasdaq approval. With a going concern warning and dwindling cash, the restructuring is a high-stakes bet that O'Leary can deliver the listing and the capital raise before the company runs out of runway.
At the time of this filing, HLYK was trading at $2.95 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $1.06 to $6.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.